Abstract CT096: Trastuzumab emtansine (T-DM1) + capecitabine in HER2-positive metastatic breast cancer (mBC) and HER2-positive locally advanced (LA)/metastatic gastric cancer (mGC): Results from the phase I/randomized phase II TRAXHER2 study

Mapping Intimacies ◽

10.1158/1538-7445.am2018-ct096 ◽

2018 ◽

Cited By ~ 1

Author(s):

Javier Cortes ◽

Véronique Dieras ◽

Sylvie Lorenzen ◽

Filippo Montemurro ◽

Jorge Riera-Knorrenschild ◽

...

Keyword(s):

Breast Cancer ◽

Gastric Cancer ◽

Metastatic Breast Cancer ◽

Phase I ◽

Locally Advanced ◽

Metastatic Breast ◽

Metastatic Gastric Cancer ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Randomized Phase Ii

Download Full-text

PCN104 Cost-Utility MODEL of Trastuzumab Emtansine (T-DM1) in HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer Previously Treated with Trastuzumab and a Taxane, Compared with Capecitabine PLUS Lapatinib, Trastuzumab PLUS Capecitabine and Capecitabine ALONE in Turkey

Value in Health ◽

10.1016/j.jval.2020.08.241 ◽

2020 ◽

Vol 23 ◽

pp. S441

Author(s):

B. Akyol Ersoy ◽

E. Erdogan-Ciftci ◽

L. Yanik ◽

B. Guler ◽

G. Ozcan ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Cost Utility ◽

Trastuzumab Emtansine ◽

Utility Model ◽

Her2 Positive ◽

Previously Treated

Download Full-text

Abstract 5468: GEP01: A phase I pharmacokinetic study of lapatinib and iv vinorelbine in the treatment of HER2-positive locally advanced or metastatic breast cancer

10.1158/1538-7445.am2011-5468 ◽

2011 ◽

Author(s):

Keyvan Rezai ◽

Nicolas Isambert ◽

Etienne Brain ◽

Florence Dalenc ◽

Saïk Urien ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase I ◽

Pharmacokinetic Study ◽

Locally Advanced ◽

Metastatic Breast ◽

Her2 Positive

Download Full-text

Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System

Clinical Drug Investigation ◽

10.1007/s40261-015-0302-x ◽

2015 ◽

Vol 35 (8) ◽

pp. 487-493 ◽

Cited By ~ 3

Author(s):

Charles Piwko ◽

Catherine Prady ◽

Simon Yunger ◽

Erika Pollex ◽

Aurelie Moser

Keyword(s):

Breast Cancer ◽

Health Care ◽

Metastatic Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Canadian Health Care System ◽

Canadian Health ◽

Canadian Health Care

Download Full-text

Results from Emilia, A Phase 3 Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine (X) and Lapatinib (L) in Her2-Positive Locally Advanced or Metastatic Breast Cancer (MBC)

Annals of Oncology ◽

10.1016/s0923-7534(20)34362-3 ◽

2012 ◽

Vol 23 ◽

pp. ixe5-ixe6 ◽

Cited By ~ 1

Author(s):

S. Verma ◽

D. Miles ◽

L. Gianni ◽

I. Krop ◽

M. Welslau ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Phase 3

Download Full-text

Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-019-03852-z ◽

2019 ◽

Vol 84 (1) ◽

pp. 175-185 ◽

Cited By ~ 2

Author(s):

Dan Lu ◽

Chunze Li ◽

Matthew Riggs ◽

Daniel Polhamus ◽

Jonathan French ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cancer Patients ◽

Single Agent ◽

Locally Advanced ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Positive Breast Cancer

Download Full-text

Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study

Annals of Oncology ◽

10.1093/annonc/mdw157 ◽

2016 ◽

Vol 27 (7) ◽

pp. 1249-1256 ◽

Cited By ~ 14

Author(s):

M. Martin ◽

P. Fumoleau ◽

J.A. Dewar ◽

J. Albanell ◽

S.A. Limentani ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Phase Ib

Download Full-text

Abstract OT-28-03: VICKI: A Phase Ib/II, randomized, placebo-controlled, study of venetoclax plus ado-trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs20-ot-28-03 ◽

2021 ◽

Author(s):

Geoffrey J Lindeman ◽

Erika Hamilton ◽

Ian Krop ◽

Bora Lim ◽

Shanu Modi ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Controlled Study ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Phase Ib ◽

Previously Treated

Download Full-text

Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer

Breast Cancer Research ◽

10.1186/bcr3661 ◽

2014 ◽

Vol 16 (3) ◽

Cited By ~ 30

Author(s):

Edith A Perez ◽

Sara A Hurvitz ◽

Lukas C Amler ◽

Kirsten E Mundt ◽

Vivian Ng ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Expression ◽

First Line ◽

Her2 Positive ◽

Randomized Phase Ii

Download Full-text

P1-12-02: Patient-Reported Outcomes (PROs) from a Randomized Phase II Study (TDM4450g/BO21976) of Trastuzumab Emtansine (T-DM1) vs Trastuzumab Plus Docetaxel (HT) in Previously Untreated HER2−Positive Metastatic Breast Cancer (MBC).

10.1158/0008-5472.sabcs11-p1-12-02 ◽

2011 ◽

Cited By ~ 2

Author(s):

GV Bianchi ◽

J Kocsis ◽

L Dirix ◽

Y Torigoe ◽

D Lalla ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Patient Reported Outcomes ◽

Phase Ii Study ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Randomized Phase Ii ◽

Patient Reported

Download Full-text

Abstract P5-18-05: Interim Results from a Phase 1b/2a Study of Trastuzumab Emtansine and Docetaxel, With and Without Pertuzumab, in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer

10.1158/0008-5472.sabcs12-p5-18-05 ◽

2012 ◽

Cited By ~ 2

Author(s):

M Martin ◽

JÁ García-Sáenz ◽

JA Dewar ◽

J Albanell ◽

SA Limentani ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Phase 1B

Download Full-text